Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress

About this update from Atara Biotherapeutics, Inc.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":3000,"height":912,"url":"https://media.zenfs.com/en/business-wire.com/20d4d25ae00f41b1aeb7ded2951d5041"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.gnsknYt.vyIBu723PFhHw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI5MjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/20d4d25ae00f41b1aeb7ded2951d5041","width":960,"height":292},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/TQNjC5fFg07W2Om5T6ZEaw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTE5NTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/20d4d25ae00f41b1aeb7ded2951d5041","width":640,"height":195},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/dvq2Utssz8yOyHYmxR4U.w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03MzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/20d4d25ae00f41b1aeb7ded2951d5041","width":1200,"height":365}},"lazy":false},{"type":"text","content":"Productive meeting held with the FDA; planning for tabelecleucel BLA resubmission","length":81,"tagName":"p","attribs":{}},{"type":"text","content":"Operating efficiencies and ATM proceeds extend cash runway into mid-2027","length":72,"tagName":"p","attribs":{}},{"type":"text","content":"THOUSAND OAKS, Calif., May 12, 2026--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the first quarter 2026 and business updates.","length":372,"tagName":"p"},{"type":"text","content":"Tabelecleucel (tab-cel® or Ebvallo™) for Post-Transplant Lymphoproliferative Disease (PTLD)","length":91,"tagName":"p"},{"type":"text","content":"As previously communicated, Pierre Fabre Pharmaceuticals (PFP), with Atara’s support, had a productive meeting with the FDA and discussed a potential path forward to resubmitting the tab-cel Biologics License Application (BLA). The FDA agreed that a single arm study using an appropriate historical control applicable to the trial population, conducted in a pre-specified manner, could serve as an adequate and well controlled study and provide safety and efficacy data in support of a marketing application of tab-cel for the pro...

More updates from Atara Biotherapeutics, Inc.